Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 16;13:811430. doi: 10.3389/fimmu.2022.811430

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Rocha, Fagre, Latham, Cummings, Aboellail, Reigan, Aldaz, McDermott, Popichak, Kading, Schountz, Theise, Slayden and Tjalkens

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

PT150 treatment decreases expression of the inflammatory cytokine Interleukin-6 (IL-6) in lung following infection with SARS-CoV-2. There was a significant decrease in expression of TMPRSS2 in bronchiolar epithelial cells of Syrian golden hamsters infected with SARS-CoV-2 at all timepoints in animals given PT150 at 30 and 100 mg/Kg/day. Experimental groups were (A–C) SARS-CoV-2 + vehicle, (D–F), SARS-CoV-2 + 30 mg/Kg/day PT150, (G–I) SARS-CoV-2 + 100 mg/Kg/day PT150, (J) Control + vehicle. (K) Quantification of IL-6 protein expression in lung tissue. *p<0.05, **p<0.01, ****p<0.0001; ^####p<0.0001 compared to control. N=6 animals per group.